GED-aPC is an engineered analog of recombinant human activated protein C with enhanced anti-inflammatory, anti-thrombotic and strong binding to endothelial protein C receptor properties, and has broad potential
The Lucent technology is designed to treat degenerative disc disease and other common spinal maladies. Lucent intervertebral body fusion devices (IBFD) implants are manufactured from radiolucent peek-optima polymer,
The KneeAnalyzer software is completely integrated into the BMA system, allowing instantaneous analysis of the resulting image. KneeAnalyzer utilizes Optasia’s proprietary model-based vision technology to assess minimum joint-space
The initial phase of the collaboration will focus on the discovery and characterization of genetic markers relating to this disease. On successful completion of the first phase of
The new products include CitraNatal DHA, CitraNatal 90 DHA and CitraNatal Rx all of which are designed to improve the nutritional status of women and their babies. CitraNatal
The preliminary results from the first 21 patients treated in the Phase I combination trial with cisplatin showed similar results, with 14 of the patients experiencing stable disease
Virtual Radiologic intends to use the net proceeds from the offering to repay outstanding debt and for general corporate purposes. Shares of Virtual Radiologic’s common stock are listed
The agreement is effective November 1, 2007 and includes 5, 10, 15 and 20 mL single-dose vials, 50 and 100 mL pharmacy bulk packages, and 10, 15 and
A prospective, multi-center clinical trial was conducted to validate the expanded clearance for CellSearch. The study, which took place in 55 clinical centers in US and Europe, involved
The biologics license application submission is based on results from five international Phase III studies which demonstrated Actemra as monotherapy or in combination with disease modifying anti-rheumatic drugs
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.